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Received November 15, 2011; accepted February 22, 2012AbstractBackground: Postirradiation otitis media with effusion (OME) is the most common radiotherapy-associated otologic complication associated
with nasopharyngeal carcinoma (NPC). This study’s aim was to evaluate the efficacy of laser myringotomy followed by intratympanic steroid
injection (LMIS) for treating OME in postirradiated NPC patients.
Methods: From August 2002 to January 2006, 27 newly diagnosed NPC patients who developed OME after a full course of radiotherapy were
enrolled. Laser myringotomy was performed followed by once-weekly administration of steroids (0.5 mL dexamethasone at a concentration of
5.0 mg/mL) into the middle ear for 3 consecutive weeks. The success rate of dry eardrum perforation and the prognostic factors associated with
OME resolution were analyzed.
Results: The procedure was performed on 44 ears of 27 patients. The mean follow-up period was 37 weeks. Of the 44 ears, 23 (52.3%) developed
persistent eardrum perforation, 18 (40.9%) developed recurrent OME, and three (6.8%) were disease-free on follow-up. Of the 23 ears with
persistent eardrum perforation, 18 (78.3%) were diagnosed as dry perforation. The absence of pretreatment mastoiditis was an independent
factor associated with OME resolution ( p< 0.001).
Conclusion: LMIS is a quick, minimally invasive, office-based technique that can be repeatedly performed to treat highly recurrent post-
irradiation OME, and it results in relatively slight pain to NPC patients. Long-lasting dry eardrum perforation allows for adequate middle ear
ventilation and drainage and guarantees sustained relief from symptoms. The absence of preoperative mastoiditis is a favorable prognostic factor
associated with OME resolution.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Nasopharyngeal carcinoma (NPC) is a widely prevalent
malignancy in Southeast Asia. The mainstay of treatment is
definitive radiotherapy.1 Although recent advances in imaging
and therapeutic techniques have reduced radiotherapy-
associated complications, the exposure of nontarget organs* Corresponding author. Dr. An-Suey Shiao, Department of Otorhinolaryn-
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doi:10.1016/j.jcma.2012.04.016during head and neck irradiation is often inevitable. Of the
various otologic complications, postirradiation otitis media-
with effusion (OME) is the most common problem,2 and this
significantly impairs the quality of life of postirradiated NPC
patients with symptoms such as conductive hearing loss, ear
discomfort, and muffling. The conventional treatments of
postirradiation OME include simple tympanic aspiration,
incisional myringotomy, and ventilation tube insertion.
Unfortunately, simple tympanic aspiration and incisional
myringotomy provide no meaningful therapeutic effects due to
their short healing times of only 1e2 days.3,4 On the other
hand, ventilation tube insertion may cause adverse effects,hinese Medical Association. All rights reserved.
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29e64%.5e7 Thus, conventional approaches often fail to
provide satisfactory relief of otologic symptoms.
Laser myringotomy has been used to treat conventional
nonirradiation-related OME.8,9 Recently, the use of laser
myringotomy has been proposed by Hwang et al as an alter-
native approach for treating NPC patients with OME.6 The
duration of relief from otologic symptoms using this method is
longer than that of simple tympanic aspiration. In addition, the
efficacy and complication rates of laser myringotomy are
similar to those of simple myringotomy. However, the study
by Huang et al enrolled both pre- and postirradiated NPC
patients; thus, the clinical utility of using laser myringotomy
to treat postirradiation OME remains unknown. On the other
hand, radiation-compromised inflammation of the middle ear
plays an important role in the pathogenesis of postirradiation
OME, while Eustachian tube dysfunction is the major cause of
nonirradiation-related OME.2,5,10e13 This may partly explain
the poor outcomes of postirradiation OME treated using
conventional approaches.
In the present study, a new therapeutic strategy was
developed that uses laser myringotomy followed by intra-
tympanic steroid injection (LMIS) to treat postirradiation
OME in NPC patients due to its distinct pathogenesis. The
goal of LMIS is to create a long-lasting dry eardrum perfo-
ration that achieves immediate symptom relief and provides
a long-term satisfactory outcome. This study’s aim was to
evaluate the efficacy of LMIS for the treatment of post-
irradiation OME in NPC patients.
2. Methods
From August 2002 to January 2006, 27 patients with newly
diagnosed primary NPC who were being treated at Taipei
Veterans General Hospital were enrolled. None of these
patients had been diagnosed with OME before NPC, and they
only developed OME after a course of radiotherapy. Patients
with recurrent OME after radiotherapy were excluded. Post-
irradiation OME was defined as the accumulation of effusion
in the middle ear without signs of acute infection. Diagnosis
was clinically confirmed by the use of video telescopy, audi-
ometry, and tympanometry (type B tympanogram). The
hospital’s institutional review board approved this study, and
all of the patients provided written informed consent.
Temporal bone computed tomography (CT) and Eustachian
tube function tests were performed on 21 patients prior to
LMIS, while six did not complete these examinations.
Evidence of mastoiditis by CT imaging included: (1) clouding
of the air cells or destruction of the mastoid outline; (2) loss of
or a decrease in the sharpness of the bony septa within the air
cells; (3) loss of the bony septa between the air cells (coa-
lescence of mastoid air cells); and (4) hypoaeration of the
mastoid. Patients with all these features on CTwere diagnosed
with “positive mastoiditis,” otherwise they were diagnosed
with “negative mastoiditis.” The pressure equalization test was
used to evaluate Eustachian tube function. Positive and
negative pressures were applied to the middle ear, and theresidual pressure was measured after several deglutinations. If
equilibration of the middle ear pressure was successfully
achieved, Eustachian tube function was considered “good,”
otherwise function was considered “poor.”
In terms of the therapeutic strategy, the surgical procedure
began by anesthetizing the eardrum using 10% topical lido-
caine for 15 minutes. The solution was then suctioned from the
ear canal. Circular laser myringotomy was performed using
a CO2 flash-scanner laser (OtoLAM; Lumenis Ltd., Yokneam,
Israel) that was applied to the lower anterior or lower posterior
quadrant of the eardrum according to the patient’s external ear
canal anatomy. The power of the CO2 laser was set to 15 W,
the spot size was 1.9 mm, and single-pulse duration of 0.2
seconds was applied. Middle ear fluid was obtained for
culturing using a sterile nonrefluxing suction bottle. Steroids
(0.5 mL dexamethasone at a concentration of 5 mg/mL) were
injected directly through the myringotomy into the middle ear
as the patient was lying on his side for 30 minutes. An
intratympanic injection of dexamethasone was administered
once per week for 3 consecutive weeks. The pre- and post-
LMIS otoscopic findings are shown in Fig. 1.
Following treatment, the patients received follow-up exam-
inations once per week for 3 weeks and then once every 2e4
weeks thereafter. OME resolution (i.e., disease-free status) was
defined as the disappearance of aural fullness, normal findings
onvideo telescopy, and typeA tympanogram.Data on sex, age at
surgery, NPC stage according to the 2002 American Joint
Committee on Cancer (AJCC) staging system,14 radiation dose,
eardrum condition, perforation healing time, recurrent disease,
complications, mastoiditis, and Eustachian tube function were
collected and analyzed in order to build a statistical model that
could be used to investigate the prognostic factors associated
with treatment outcomes.
Univariate cross-tabulation analysis and Pearson’s Chi-
square test were used to assess associations between
pretreatment variables (e.g., mastoiditis and Eustachian tube
function) and treatment outcomes. All statistical comparisons
and descriptive statistics were performed using the SPSS
statistical software package (version 18.0; SPSS, Inc., Chi-
cago, IL, USA). A p value of < 0.05 was considered statis-
tically significant.
3. Results
The patient characteristics are summarized in Table 1.
Laser myringotomy was performed on 44 ears of 27 patients.
Of these 27 patients, 12 (44%) were female and 15 (56%) were
male. Seventeen patients (63%) had experienced bilateral
postirradiation OME. Eleven patients were classified as AJCC
2002 stage IeII disease and 16 patients were classified as
stage IIIeIV disease. The mean age at the time of surgery was
53 years (range: 33e79 years). The mean radiation dose was
70.28 Gy. The mean follow-up period was 36.7 weeks (range:
4e112 weeks). The fluid content of the middle ear effusions
was serous in all patients. There were no postoperative
complications such as sensorineural hearing loss, nystagmus,
or vertigo.
Fig. 1. Otitis media with effusion of the right ear (A) before and (B) after laser myringotomy followed by once-weekly intratympanic steroid injection for 3
consecutive weeks. Dry perforation of the eardrum resulted and was maintained for adequate middle ear ventilation and drainage, allowing the immediate and
sustained relief of otologic symptoms.
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irradiation OME in NPC patients are shown in Table 2. Of the
44 ears that were treated, 23 (52.3%) were diagnosed as
persistent eardrum perforation, 18 (40.9%) were diagnosed as
recurrent OME, and three (6.8%) were disease-free. Of the 23
ears with persistent eardrum perforation, 18 (up to 78.3%)
demonstrated dry perforation and only five (21.7%) demon-
strated persistent otorrhea. The mean follow-up period for the
18 ears with dry eardrum perforation was 36.7 weeks (range:
16e89 weeks). The mean healing time following laser myr-
ingotomy of the 21 ears (18 recurrent OME ears and 3 disease-
free ears) was 6.5 weeks (range: 1e24 weeks). OME recurred
in 18 ears with intact eardrums about 3e4 months after LMIS,
and all of these ears were treated using repeated LMIS. No
NPC recurrence was observed in the 18 patients with recurrent
OME, as shown on follow-up magnetic resonance imaging
(MRI) examinations of the head and neck regions. Following
repeated LMIS, some patients were lost on follow-up and
some required even more additional LMIS.
The bacteriological isolates obtained from the middle ear
effusions during surgery are shown in Table 3. Repeated












Average radiation dose (Gy) 70.28
Abbreviations: NPC, nasopharyngeal carcinoma.residual effusion in the middle ear. In total, 62 culture samples
were obtained from 44 ears of 27 patients, yielding 22 isolates.
The positive culture rate was only 35.5% (22 isolates from 62
culture samples). The predominant organism was Staphylo-
coccus aureus, which accounted for 59.1% of all isolates (13
of 22 isolates).
Temporal bone CTwas performed on 33 ears of 21 patients
(Table 4), indicating that 23 ears were complicated by
mastoiditis prior to LMIS. None of these patients were
disease-free at the end of the follow-up period. Of the other 10
ears that were not complicated by pre-LMIS mastoiditis, three
(30%) were disease-free at the end of follow-up. Post-
irradiation OME patients without mastoiditis demonstrated
a significantly higher resolution rate of OME (i.e., disease-free
status) than patients with mastoiditis ( p< 0.001).
Similarly, Eustachian tube function testing was performed
on 33 ears of 21 patients (Table 4). Of these 33 ears, 24 ears
demonstrated good Eustachian tube function prior to LMIS
and two ears (9%; 2 of 24 ears) were disease-free at the end of
the follow-up period. Of the other nine ears with poor
Eustachian tube function, one (11%; 1 of 9 ears) was disease-
free at the end of the follow-up period. There was no signifi-
cant difference in terms of the OME resolution rate between
the ears with good and poor Eustachian tube functions
(p¼ 0.637).Table 2
Clinical outcomes.
Clinical outcome Ears Percentage
Persistent eardrum Perforation (n¼ 23)
Dry 18 40.9%
Wet 5 11.4%
Intact eardrum (n¼ 21)
Recurrent OME 18 40.9%
OME resolution 3 6.8%
Total 44 100%
Abbreviations: OME, otitis media with effusion.
Table 3
Bacteriological isolates from middle ear effusions obtained during surgery.
Organism No. of cultures Percentage
No growth 40 64.5%
Staphylococcus aureus 13 21.1%
MRSA 3 4.8%
Enterococcus 1 1.6%
Gram-positive bacilli 1 1.6%
Klebsiella pneumonia 1 1.6%
Micrococcus sp. 1 1.6%
Pseudomonas aeruginosa 1 1.6%
Mold 1 1.6%
Total 62 100%
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus.
332 C.-L. Kuo et al. / Journal of the Chinese Medical Association 75 (2012) 329e3344. Discussion
OME is the most common otologic toxicity that presents in
NPC patients after radiotherapy. Its morbidity rate has been
reported to be as high as 53%.13 Nelson et al reported that 23%
of NPC patients in their study developed OME within 2 years
of completing radiotherapy.7 The pathogenesis of post-
irradiation OME is quite different from that of nonirradiation-
related OME, which is commonly caused by Eustachian tube
dysfunction.2,15,16 Furthermore, patients with nonirradiation-
related OME usually demonstrate favorable results following
conventional treatment.2 The complete resolution of effusion
can even be achieved after the restoration of tubal functions. In
contrast, in postirradiation OME, the generally acknowledged
etiologies are associated with direct radiation damage,2,16
including scarring of the Eustachian tube opening, poor
mucociliary function of the Eustachian tube, and fibrosis of the
tensor veli palatini muscle. However, an important but
frequently ignored cause is radiation-compromised inflam-
mation of the middle ear.2,5,10e13,15,16
There are controversies regarding the potential benefits of the
conventional approaches used to treat postirradiation OME due
to disappointing long-term treatment results.2,6,16 However,
theremay be several explanations for these poor outcomes. First,
the recurrence rate of postirradiation OME is high (range:
77.8e88.9%), whereas the cure rate is low (range:
8.7e18.2%).2,6,16 This may be due to irreversible radiation
damage to the Eustachian tube and middle ear mucosa. Second,Table 4






Mastoiditis (n¼ 33)a < 0.001
Positive (n¼ 23) 23 (100%) 0
Negative (n¼ 10) 7 (70%) 3 (30%)
Eustachian tube function (n¼ 33)a 0.637
Good (n¼ 24) 22 (91%) 2 (9%)
Poor (n¼ 9) 8 (89%) 1 (11%)
Abbreviations: OME, otitis media with effusion; CT, computed tomography.
a Thirty-three ears of 21 patients underwent temporal bone CT and Eusta-
chian tube function tests before treatment.
b Disease status included persistent eardrum perforation and recurrent
disease.simple tympanic aspiration or incisional myringotomy alone is
ineffective due to the short duration of the perforation healing
time (usually only 1e2 days).3,4 In fact, 3 weeks is regarded as
the shortest time required for transtympanic ventilation.6,17 The
ventilation tube, in comparison, requires an indwelling period of
4e6months4,6 and is usually associatedwith a high incidence of
postoperativemiddle ear infection and otorrhea, which are often
refractory to local or medical treatment.6,7,13 Thus, the effec-
tiveness of conventional methods of the treatment of post-
irradiation OME remains questionable.
To solve the troubling problems associated with post-
irradiation OME, many otologists have shifted their focus to
alternative approaches, and laser myringotomy seems to be
a promising alternative choice. Laser myringotomy was first
applied to the human eardrum in 1982 by Goode,18 who
reported that myringotomy using a CO2 laser provides more
prolonged eardrum perforation than incisional myringotomy
using a knife. In the past decade, laser myringotomy has
generated increased interest in its clinical applications for the
treatment OME.3,4,19e23 Advocates claim that its advantages
over conventional treatments include the avoidance of general
anesthesia, convenience of an office-based model, time and
cost effectiveness, and reduced eardrum damage.19,23
Accordingly, laser myringotomy is considered a safe and
practical procedure for treating OME.
Unfortunately, the use of laser myringotomy for treating
postirradiation OME in NPC patients is rarely discussed in the
literature, usually because NPC patients are intentionally
excluded as a separate entity fromOME. To date, only one study,
whichwas conducted byHwanget al in 2005, has been conducted
on the effectiveness of using laser myringotomy to treat NPC
patients.6 However, both pre- and postirradiated NPC patients
were enrolled in that study; thus, the usefulness of laser myr-
ingotomy for treating radiation-related OME remains uncertain.
In response to the complex and delicate process of OME
formation in postirradiated NPC patients, this study proposes
a new therapeutic strategydLMISdthat can not only provide
ventilation to the middle ear but also treat radiation-
compromised inflammation of the middle ear. This study is
the first analysis of the effectiveness of laser myringotomy for
treating postirradiation OME in NPC patients. Radiation can
cause irreversible damage to the Eustachian tube and middle
ear mucosa, inevitably resulting in a high recurrence rate
(77.8e88.9%) and a low cure rate (8.7e18.2%).2,6,16 There-
fore, the therapeutic goal of LMIS is to provide sustained
relief of otologic symptoms instead of a cure. In other words,
LMIS is designed to create a long-lasting dry perforation of
the eardrum, which allows the maintenance of middle ear
ventilation and long-term relief of tubal dysfunction-related
symptoms such as ear discomfort and muffling.
In the current study, the rate of persistent dry eardrum
perforation is 41% (18 of 44 ears). In contrast, Liang et al
reported a relatively low rate of dry eardrum perforation (4%;
1 of 23 ears) with ventilation tube insertion for the treatment
of postirradiation OME in NPC patients.16 Xu et al also
reported low rates of dry eardrum perforation using conven-
tional approaches (e.g., auripuncture, auripuncture with
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treating OME in postirradiated NPC patients (11%, 5 of 45
ears; 16%, 7 of 45 ears; and 11%, 5/45 ears, respectively).2
Compared with the results of the conventional approaches
reported in the literature, LMIS demonstrates a significantly
higher success rate of dry eardrum perforation (all p< 0.01).
Using the same laser myringotomy technique as the current
study, Hwang et al reported a 24% rate (16 of 68 ears) of dry
eardrum perforation when treating NPC patients with OME.6
Furthermore, the results of the current study show a long-
lasting period of dry eardrum perforation (mean: 36.7
weeks; range: 16e89 weeks). Therefore, LMIS may be
effective for treating postirradiation OME in NPC patients, as
evidenced by the higher rate of dry eardrum perforation over
a longer period of time.
Dry eardrum perforation or a dry middle ear is indicative of
a restored mucosal immune system and complete remission of
otorrhea, which are the most common results of ventilation tube
insertion.5e7 Immune system restoration in the middle ear mucosa
may result from the administration of topical steroids. The
proposed mechanisms for the actions of steroids on OME include
direct anti-inflammatory actions on the middle ear and Eustachian
tube, improved tubal function due to increased Eustachian tube
surfactant concentration and shrinkage of peritubal lymphoid
tissue, reduced middle ear fluid viscosity via mucoprotein effects,
downregulation of inflammatory cytokine production by gluco-
corticoids, and the upregulation of sodium transport in the middle
ear epithelia resulting in increased fluid clearance.24e26 By
reducing inflammation and epithelial repair of the middle ear
mucosa, LMIS can accelerate the resolution of postirradiation
OME and provide long-lasting and significant relief of symptoms.
Intratympanic injection of dexamethasone is a safe and
simple intervention that significantly delays the healing of
eardrum perforation without long-term perforations.27e29
Antonelli et al reported a transtympanic ventilation time of
at least 4 weeks through delayed-healing perforation.27
However, this study was conducted using an animal model
and the topical agent was prepared from ciprofloxacin-
dexamethasone solutions. The true effect of dexamethasone
on the healing process of human eardrum perforation remains
uncertain. Among the 21 ears that demonstrated complete
healing in the current study, the mean perforation healing time
was 6.5 weeks (range: 1e24 weeks). This may be the first
human model to estimate the effect of steroids on delaying
healing following eardrum perforation.
The 40.9% recurrence rate determined in the current study is
lower than those reported in previously published studies
(77.8e88.9%),2,16 although the cure rate (6.8%) is similar to
those previously published in the literature (8.7e18.2%).2,16
The recurrence rate determined here is not inconsequential,
and even if only three ears (6.8%) attained the complete reso-
lution of OME, this is balanced by the advantages of LMIS:
namely, this quick, minimally-invasive, office-based technique
allows for repeated procedures with minimal patient pain.
Although the fluid content of the middle ear effusions was
serous in all patients, all of the middle ear discharge samples
were sent for culturing. The positive culture rate was not high(35.5%; 22 isolates recovered from 62 culture samples) and S
aureus was the predominant organism, which accounted for
59.1% of all of the recovered isolates. Thus, in cases of serous
discharge, the use of pre- and postoperative topical and oral
antibiotics may be controversial.
To identify the potential risk factors associated with the
clinical outcomes (i.e., OME resolution), patients were further
investigated in terms of the clinical factors of mastoiditis
(positive vs. negative) and Eustachian tube function (good vs.
poor). Information on the effects of these risk factors is
genuinely beneficial for predicting treatment outcomes.
Mastoiditis before LMIS was shown to be an independent
factor associated with clinical outcome: i.e., a good mastoid
status predicts a good clinical outcome ( p< 0.001). However,
pretreatment Eustachian tube function was not associated with
treatment outcome ( p¼ 0.637).
This study has several limitations. First, it is limited by the
small number of patients that were enrolled. Thus, it is diffi-
cult to evaluate the impact of the stage or the total dose of
radiation on the outcomes of LMIS. There may also be
unavoidable selection bias, and some unnoticed confounding
factors may not have been included in the univariate analysis
used to prove the independent correlations with clinical
outcomes. This study is also limited by the short-term results.
Lastly, further prospectively randomized research with
a control group is required to investigate the potential benefits
of applying the newly proposed therapeutic strategy.
In conclusion, the preliminary results of this study provide
further supportive evidence of the use of LMIS to treat post-
irradiation OME in NPC patients. This new therapeutic strategy
may provide both short- and long-term relief of symptoms. This
convenient and minimally invasive treatment, which does not
require general anesthesia, allows for repeated procedures with
little pain in patients with OME recurrence. Therefore, LMIS may
be a practical alternative to conventional approaches for treating
NPC patients with postirradiation OME.References
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